Aileron Therapeutics (RNTX) Enterprise Value to EBITDA Ratio

Public company logo of aileronrx.com (RNTX)

This chart of Rein Therapeutics Inc (RNTX) stock quotes demonstrates an EV/EBITDA of 0.00. The business relies on external laboratories (CRO), fully delegating production and testing to contractors. The company's fate is tied to the results of drug trials, which creates significant risks due to the absence of regular profits. Price action is driven by the specifics of R&D processes, ignoring general market trends and macroeconomics.

Rein Therapeutics Inc. - RNTX Company Value to EBITDA (period 11/23/2025 - 11/16/2026)

Comprehensive metric breakdowns and analytics for Rein Therapeutics Inc. (RNTX)

- current price and projected stock value:
Fundamental valuation:Rein Therapeutics Inc RNTX
Manufactured products of Rein Therapeutics

The EV/EBITDA ratio determines the objective enterprise value by comparing the total cost of acquiring a business, including debt and taxes, against its operating profitability. By analyzing the EV/EBITDA chart with historical data for Rein Therapeutics Inc. (RNTX), an investor can assess the efficiency of capital expenditures in screening robotization and software data automation, revealing the company's actual capitalization trend.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|Enterprise Value to EBITDA Ratio BGM|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Biosciences, Inc.)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma Holdings)|KROS (Keros Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharma) - Company Value to Operating Income Before Depreciation Ratio|Kamada Ltd. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Therapeutics)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group PLC (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics Inc. (APLT)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI